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Abstract 
UK Biobank is a population-based cohort of 500,000 participants recruited between 2006 and 
2010. Approximately 9.2 million individuals aged 40-69 years who lived within 25 miles of 
the 22 assessment centres in England, Wales and Scotland were invited, and 5.4% participated 
in the baseline assessment. The representativeness of the UK Biobank cohort was investigated 
by comparing demographic characteristics between non-responders and responders. 
Sociodemographic, physical, lifestyle and health-related characteristics of the cohort were 
compared with nationally representative data sources. UK Biobank participants were more 
likely to be older, women and to live in less socioeconomically deprived areas than non-
participants. Compared with the general population, participants were less likely to be obese, 
smoke, drink alcohol on a daily basis and had fewer self-reported health outcomes. Rates of 
all-cause mortality and total cancer incidence (at age 70-74 years) were 46.2% and 11.8% 
lower in men, and 55.5% and 18.1% lower in women, respectively, than the general 
population of the same age. UK Biobank is not representative of the sampling population, 
with evidence of a ‘healthy volunteer’ selection bias. Nonetheless, the valid assessment of 
exposure-disease relationships may be widely generalizable and does not require participants 
to be representative of the population at large.  
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UK Biobank is a large prospective study, primarily established to investigate the genetic and 
lifestyle determinants of a wide range of diseases of middle and later life (1).
 
The open access 
resource involves 500,000 men and women who were aged 40-69 years when recruited during 
2006 and 2010 throughout England, Wales and Scotland. Extensive questionnaire data, 
physical measures and biological samples were collected at recruitment, with ongoing 
enhanced data collection in large subsets of the cohort, including a repeat baseline 
assessment, genotyping, biochemical assays, web-based questionnaires, physical activity 
monitoring and multimodal imaging. All participants are followed-up for health outcomes 
through linkage to national electronic health-related datasets. 
The aim of the current study is to examine and quantify whether the UK Biobank cohort 
differs from the sampling frame on a range of characteristics due to the ‘healthy volunteer 
effect’ (2), whereby volunteering participants, tend to be, on average, more health-conscious 
than non-participants (3). To investigate this, the distribution of a range of sociodemographic, 
physical, lifestyle and health-related characteristics was compared between UK Biobank 
participants and (a) those invited to join UK Biobank and (b) findings from nationally 
representative surveys. 
 
METHODS 
UK Biobank sent postal invitations to 9,238,453 individuals registered with the National 
Health Service who were aged 40-69 years and lived within approximately 25 miles of one of 
22 assessment centres located throughout England, Wales and Scotland. Approval was 
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obtained from the National Information Governance Board for Health and Social Care and the 
North-West Multicentre Research Ethics Committee for local National Health Service 
Primary Care Trusts to provide UK Biobank with contact details of people within the eligible 
age range and for us to retain limited information on non-responders. Overall, 503,317 
participants consented to join the study and attended an assessment centre between 2006 and 
2010, resulting in a participation rate of 5.44% (see Web Figure 1 for flow chart 
demonstrating responses to invitations).  
Anonymised data on sex, month and year of birth, Townsend deprivation index (an indicator 
of socioeconomic status) and geographic location are stored by UK Biobank and are available 
for 8,761,869 out of 9,238,453 (94.8%) of the individuals sent an invitation letter, allowing 
these characteristics to be compared between non-participating invitees and participants. The 
distribution of a range of sociodemographic, physical, lifestyle and health-related 
characteristics of the UK Biobank cohort was also compared with publicly available summary 
data from nationally representative population-based surveys and the UK Census. We selected 
summary survey data that matched the UK Biobank cohort as closely as possible with regard 
to population demographics (i.e. mixed gender and aged 40-69 years) and period of data 
collection (2006 to 2010). Where certain characteristics from the national survey summary 
data were only available in pre-specified aggregated age and sex subgroups, UK Biobank data 
was stratified into similar groups for comparative purposes. Formal statistical tests of the 
difference in characteristics between UK Biobank and national data were not performed 
because of the lack of variance measures required to test for differences between means, such 
as standard deviations, from the comparison populations.   
The UK Census collects individual and household-level demographic data every 10 years for 
the whole UK population. Data on ethnicity was obtained from the 2001 and the 2011 UK 
Census for England, Scotland and Wales (as these reflect the census years before and 
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immediately after the recruitment period) (4,5). Data on property ownership status was 
obtained from the 2001 UK Census for England and Wales only (as 2011 UK Census data on 
property ownership was not available for the appropriate age groups). Data on anthropometric 
measures, smoking status, alcohol consumption and prevalence of self-reported health 
outcomes were obtained from the Health Survey for England (HSE) performed in 2006, 2008, 
2009 and 2010 (6–9). The HSE consists of an annual cross-sectional survey of a small 
(n=~5,000 to ~15,000) representative population of England through a two-stage random 
probability sampling process, with different data items collected on a different population 
each year (10,11). Since 2003, HSE has incorporated weighting to account for non-response 
bias (12). This includes different weights for non-responding households, non-responding 
individuals in responding households and non-response at different stages of data collection. 
For a detailed description of the data collection methods in UK Biobank and national surveys, 
see Web Table 1.  
Data on age and sex-specific all-cause mortality and cancer incidence rates for England were 
obtained from the Office for National Statistics for 2012 (as this date represents the midpoint 
of the follow-up period for UK Biobank participants) (13,14). For all-cause mortality, follow-
up time (person-years) in the UK Biobank cohort was calculated as the age at recruitment to 
the age at death or date of complete follow-up (30
th
 November 2015), whichever came first; 
for cancer incidence rates, follow-up time was defined as the age at recruitment to the age at 
first cancer diagnosis, death or date of complete follow-up (30
th
 September 2014), whichever 
came first (among individuals with no cancer at recruitment based on cancer registry data). 
Incidence rates were calculated for total cancer (excluding non-melanoma skin cancer), 
defined using International Classification of Diseases-10 (ICD-10) C00-C97 excluding C44, 
and common subtypes; prostate (ICD-10; C61), breast (ICD-10; C50), colorectal (ICD-10; 
C18-20), lung (ICD-10; C33-34), endometrium (ICD-10; C54) and kidney (ICD-10; C64). 
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Ethical statement 
UK Biobank received approval from the National Information Governance Board for Health 
and Social Care and the National Health Service North West Centre for Research Ethics 
Committee (Ref: 11/NW/0382).  
 
RESULTS 
Characteristics of UK Biobank participants versus non-participating invitees  
Of the 9,238,453 men and women invited to join UK Biobank, 503,317 (5.45%) consented 
and were recruited between 2006-2010. Overall, the participation rate was higher in women 
(6.4% and 5.1% in women and men, respectively) (Figure 1A), higher in older age groups 
(9% in those aged ≥60 years and 3% in those aged 40-44 years) (Figure 1B) and higher in less 
socioeconomically deprived areas (8.3% in those from the least deprived areas and 3.1% in 
those from the most deprived areas) (Figure 1C). Participation rates showed regional 
differences, being highest in South West England (9.6%) and East Scotland (8.2%) and lowest 
in West Scotland (4.3%), London, West Midlands and North West England (all 4.7%) (Figure 
1D, also see Web Table 2 for further details). 
 
Characteristics of UK Biobank participants compared with national survey data  
Sociodemographic factors  
In UK Biobank, 94.6% of participants were of white ethnic background, which was similar to 
that of the national population of the same age range taken from the 2001 UK Census 
(94.5%), but somewhat higher than the 2011 Census (91.3%; Table 1). UK Biobank 
participants were also more likely to own their property outright and were less likely to have a 
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mortgage or loan, have shared ownership or live in rental accommodation than the general 
population of the same age range (Table 2). 
 
Physical characteristics 
UK Biobank participants were, on average, taller, leaner and had a smaller waist 
circumference than the general population, based on the HSE 2008 (Table 3). For example, 
mean body mass index (defined as weight [kg]/height [m]
2
) in UK Biobank men and women 
aged 55-64 years was 27.9 and 27.7, respectively, compared with 28.5 and 28.0 in the general 
population, based on data from the HSE 2008. UK Biobank men and women were also less 
likely to be obese (defined as body mass index ≥30 kg/m2) across all age groups examined, 
compared with the general population. For example, for men aged 45-54 years, the prevalence 
of obesity was 25.6% in UK Biobank and 31.5% in the general population, with 
corresponding values of 23.0% and 32.2% for women, respectively (Web Table 3). 
 
Lifestyle characteristics 
UK Biobank men and women were less likely to be current smokers across all ages than the 
general population based on data from the HSE 2008 (Figure 2). For example, for men aged 
45-54 years, the prevalence of current smoking was 15% in UK Biobank and 22% in the 
general population (Figure 2C); the corresponding values for women were 11% and 20%, 
respectively (Figure 2D). However, younger smokers (aged 45-54 years) in UK Biobank 
smoked more heavily (≥20 cigarettes per day) than the general population (46% and 41%, 
respectively for men; 32% and 28%, respectively for women). This difference persisted for 
older women aged 55-64 years (31% and 23% in UK Biobank and the general population, 
respectively) but not for older men (47% and 49%, respectively; Web Figure 2). UK Biobank 
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participants were also less likely to be never-drinkers but were less likely to drink every day 
compared with the general population included in the HSE 2008 (Table 4).  
 
Self-reported health outcomes 
UK Biobank participants had a lower prevalence of self-reported health outcomes, including 
cardiovascular disease, stroke, hypertension, diabetes, chronic kidney disease and respiratory 
disease compared with the general population, as obtained from various surveys of the HSE 
performed in 2006, 2009 and 2010 (Table 5). For example, for those aged 45-54 years, the 
prevalence of self-reported cardiovascular disease in UK Biobank compared with the general 
population was 4.6% and 10.9%, respectively for men and 2.4% and 10.3%, respectively for 
women.  
 
All-cause mortality and cancer incidence rates 
UK Biobank participants were followed up for a mean of 6.77 years (SD=1.01) and 5.53 years 
(SD=1.10) for all-cause mortality and incident cancer, respectively. Compared with national 
death rates in those aged 70-74 years, all-cause mortality in UK Biobank was 46.2% lower in 
men and 55.5% lower in women (Figure 3A and B; also see Web Table 4 for further details of 
age-specific mortality rates). The total cancer incidence rate was also lower than the general 
population, being 11.8% and 18.1% lower at ages 70-74 years in men and women, 
respectively (Figure 4A and B; also see Web Table 5 for further details of age-specific cancer 
incidence rates). A similar pattern was observed for cancers of the colorectum, kidney and 
endometrium (Web Figure 3). Lung cancer incidence rates in UK Biobank were markedly 
lower for both men and women, whilst rates of female breast cancer were similar to the 
national average, with the exception of ages 45-49 years, where the rate was higher in the UK 
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Biobank cohort. In contrast, prostate cancer incidence was higher in UK Biobank compared 
with national rates across all age groups examined.  
 
DISCUSSION 
The participation rate in UK Biobank was higher among women, older age groups and among 
those living in less socioeconomically deprived areas. For example, men aged 45-54 years 
were less likely to be obese (25.6% in UK Biobank versus 31.5% in the general population), 
and less likely to be current smokers (15% versus 22%), with similar findings observed for 
women and older age groups. Furthermore, compared with the general population of the same 
age, UK Biobank participants were less likely to drink on a daily basis and had fewer self-
reported health outcomes. Linkage of UK Biobank participants with their health records 
during an average of 6-7 years follow-up also showed lower rates of all-cause mortality and 
total cancer incidence than the general population of the same age group. 
These findings are consistent with the well-established “healthy volunteer” effect, which has 
been demonstrated in other volunteer-based cohort studies (15–17). Other prospective studies 
have also reported lower all-cause mortality and incident cancer rates compared with national 
rates (18–21). The only health outcome examined that was higher in UK Biobank than the 
general population was prostate cancer, which might reflect higher rates of voluntary prostate-
specific antigen testing (and subsequent prostate cancer diagnosis) among health-conscious 
men. In contrast, lung cancer incidence rates were markedly lower in UK Biobank across all 
age and sex groups, almost certainly caused by the lower prevalence of smoking compared 
with the general population. 
Because UK Biobank participants are, on average, more health-conscious than the general 
population, this cohort is not best-placed to estimate generalizable prevalence or incidence 
rates of disease (although some health-related characteristics of the UK Biobank cohort, such 
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as the prevalence of self-reported pain, have previously been shown to be similar to that of the 
national population (22)). In order for a cohort study to produce generalizable associations of 
exposures with disease, what is important is that sufficiently large numbers of individuals 
with different levels of exposures are investigated with high internal validity (23–26). Indeed, 
if one was interested in investigating the association of ethnicity with subsequent disease risk, 
the most appropriate study design would be to recruit a large number of people from different 
ethnic backgrounds rather than have a representative, largely white population. As UK 
Biobank is primarily designed for investigating exposure-disease associations, the lack of 
representativeness should not be regarded as a limitation (27,28). As with all observational 
studies, it is incumbent on researchers to acknowledge potential sources of bias on a case-by-
case basis that might affect the generalisability of exposure-disease associations, such as 
residual confounding, reverse causation and self-selection bias (24,29). Indeed, although still 
in the early stages as a prospective study, initial publications show expected associations 
between cardiometabolic morbidity, self-reported health and smoking with mortality risk 
(30,31).  
This study provides an overview of the representativeness of the UK Biobank cohort on a 
variety of key characteristics in comparison with the general population using data from 
nationally representative surveys. We expect these findings will be used by researchers to 
inform the interpretation of results or, in some instances, to help generate weighted results 
(for example, in order to estimate nationally-representative disease rates). We were able to 
compare participation rates for key sociodemographic characteristics (such as age, sex, 
socioeconomic status and geographic location) due to the availability of such data for the total 
sampling frame. The availability of follow-up health data enabled us to compare death and 
cancer incidence rates with age- and sex-specific national rates and the large size of the cohort 
meant that sufficient numbers of cases had accrued to investigate common cancer subtypes. 
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All participants are flagged by national death and cancer registries, and loss to follow-up due 
to emigration is minimal (0.3% of the cohort). Further follow-up is required to determine 
whether this ‘healthy volunteer effect’ attenuates over time (owing to the development of 
chronic disease as the cohort ages), which has been observed in previous studies (18,20,32).  
One limitation of the study is that the national survey data (available from the UK Census and 
the HSE) were presented in pre-specified age groups, thereby restricting the comparisons that 
could be performed. For the majority of characteristics, comparable national survey data was 
only available for England, although only 11% of participants were recruited in Wales and 
Scotland and the distribution of most characteristics is similar across the countries. It is also 
possible that differences in the wording of questions, answer choices and data collection 
methods might have influenced the comparability of certain characteristics between the 
national surveys and the UK Biobank cohort. For example, HSE primarily consisted of a 
verbal interview that enabled the interviewer to probe the participant for further information, 
whereas all of the characteristics presented here in UK Biobank were collected via a 
touchscreen questionnaire with the exception of self-reported illnesses, which was collected 
through a verbal interview with a trained nurse.  
In conclusion, the UK Biobank cohort is not representative of the general population on a 
number of sociodemographic, physical, lifestyle and health-related characteristics. UK 
Biobank participants generally live in less socioeconomically deprived areas and are less 
likely to be obese, to smoke, to drink on a daily basis and to have fewer self-reported diseases. 
All-cause mortality is approximately half and total cancer incidence rates are approximately 
10-20% lower that of the UK population as a whole. Although UK Biobank is not suitable for 
deriving generalizable disease prevalence and incidence rates, its large size and heterogeneity 
of exposure measures provide valid scientific inferences of associations between exposures 
and health outcomes that are generalizable to other populations. 
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Figure legends 
Figure 1. Participation rate according to A) sex, B) age at recruitment, C) Townsend 
deprivation score and D) region of residence. For numerators and denominators see Web 
Table 1. Participants were assigned a Townsend deprivation score corresponding to the output 
area of their residential postcode; most deprived = ≥2.00, average = −2.00 to 1.99, least 
deprived = <−2.00. 
 
Figure 2. Comparison of smoking status in UK Biobank participants with data from the 
Health Survey for England (HSE), 2008 for A) men aged 45-54 years, B) women aged 45-54 
years, C) men aged 55-64 years and D) women aged 55-64 years. HSE estimates weighted for 
non-response bias. Excludes 1,899 UK Biobank participants aged 45-64 with missing data for 
smoking status or who responded ‘prefer not to answer’. Number of participants: A) UK 
Biobank = 62,004, HSE = 1,206; B) UK Biobank = 79,755, HSE = 1,233; C) UK Biobank = 
94,907, HSE = 1,085; D) UK Biobank = 116,246, HSE = 1,123. See reference 9 for further 
information about HSE data. 
 
Figure 3. Comparison of (A,B) mortality rates per 1000 person-years by age at death for UK 
Biobank participants and the population of England and Wales in 2012 from the Office for 
National Statistics for A) men and B) women. Total number of deaths in UK Biobank 
participants aged 45-74: men = 8,291, women = 5,380. See reference 15 for further 
information about death registration data. 
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Figure 4. Comparison of incidence rates for all cancers excluding non-melanoma skin cancer 
(NMSC) per 100,000 person-years by age at cancer diagnosis for UK Biobank participants 
and the population of England in 2012 from the Office for National Statistics for A) men and 
B) women. Total number of all incident cancers excluding NMSC in UK Biobank participants 
aged 45-74: men = 11,436, women = 10,592. See reference 16 for further information about 
cancer registration data. 
 
Table 1. Comparison of Self-Reported Ethnic Origin of UK Biobank Participants With 
Census Data for the Age Group 40-69 Years in England, Wales and Scotland in 2001 and 
2011
a,b
  
 
 
Ethnicity 
UK Biobank 
(n=499,877) 
2001 UK Census 
(n=20,198,307) 
2011 UK Census 
(n=23,146,612) 
N % N % N  % 
   White
c 
472,837 94.6 19,085,322 94.5 21,133,317 91.3 
   Black or black British
d 
8,066 1.6 302,073 1.5 565,777 2.4 
   Mixed
e 
2,958 0.6 82,389 0.4 191,085 0.8 
   Indian 5,951 1.2 325,651 1.6 442,338 1.9 
   Pakistani 1,837 0.4 147,695 0.7 239,166 1.0 
   Bangladeshi 236 0.0 46,220 0.2 75,919 0.3 
   Chinese 1,574 0.3 70,572 0.3 109,412 0.5 
   Other Asian 1,858 0.4 73,917 0.4 240,324 1.0 
   Other ethnic group 4,560 0.9 64,468 0.3 149,274 0.6 
 
a
   See references 4-7 for further information about census data. 
b
   Excludes 2,778 UK Biobank participants aged 40-69 with missing data for ethnicity, who  
     responded ‘prefer not to answer’ or who responded ‘do not know’. 
c
   Includes the following categories; white British, white Irish and other white background.   
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d
   Includes the following categories; Caribbean, African and other black background.  
e
   Includes the following categories; white and black Caribbean, white and black African,  
    white and Asian and other mixed background. 
Table 2. Comparison of Property Ownership Status of UK Biobank Participants With Census 
Data for Age Group 50-64 Years in England and Wales in 2001
a,b 
 
 
Property ownership status 
UK Biobank 
(n=284,400) 
2001 UK census 
(n=9,098,70) 
N % N % 
   Owns outright
 
161,318 56.7 3,690,996 40.6 
   Owns with mortgage or loan
 
96,427 33.9 3,599,560 39.6 
   Shared ownership
 
682 0.2 33,971 0.4 
   Rented from council (local  
   authority), housing association or  
   registered social landlord 
16,407 5.8 1,187,422 13.1 
   Rented from private landlord   
   /letting  
   agency 
7,514 2.6 418,900 
 
4.6 
   Live in accommodation rent-free 2,052 0.7 117,344 1.3 
   Living in a communal  
   establishment
c
 
N/A N/A 49,877 0.5 
 
N/A; not available 
 
a
   See reference 4 for further information about census data. 
b
   Excludes 4,313 UK Biobank participants aged 50-64 with missing data for property  
     ownership status, who responded ‘none of the above’ or who responded ‘prefer not to  
     answer’. 
c
   Category not included in UK Biobank questionnaire. 
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Table 3. Comparison of Measured Mean Weight, Height and Waist Circumference by Age 
and Sex for UK Biobank Participants (Recruited 2006-2010) With Data From the Health 
Survey for England, 2008
a,b  
 
Anthropometric 
measures by sex 
Age 45–54 years Age 55–64 years 
UK Biobank HSE UK Biobank HSE 
N Mean 
(SD)
c
 
N Mean N Mean 
(SD)
c 
N Mean 
Men          
Body mass index
d
 61,860 27.8 (4.4) 1,059 28.1 94,776 27.9 (4.3) 968 28.5 
Weight (kg)
e
 61,929 86.9 (15.1) 1,079 86.4 94,875 86.0 (14.3) 980 86.7 
Height (cm)
f
 61,919 176.5 (6.9) 1,076 175.1 94,901 175.4 (6.7) 981 174.0 
Waist (cm)
g
 62,010 96.1 (11.5) 845 100.3 95,031 97.7 (11.4) 755 102.9 
Women         
Body mass index
d
 79,714 26.9 (5.4) 1,057 27.7 116,303 27.3 (5.1) 985 28.0 
Weight (kg)
e
 79,738 71.8 (14.8) 1,067 72.8 116,344 71.6 (13.8) 995 72.3 
Height (cm)
f
 79,792 163.4 (6.3) 1,097 162.0 116,429 162.0 (6.2) 1,016 160.5 
Waist (cm)
g
 79,809 83.6 (12.8) 850 89.3 116,471 85.5 (12.5) 784 91.6 
 
 
a
   See reference 9 for further information about HSE data. 
b
   HSE data is weighted for nonresponse bias. 
c
   Standard deviation values were not available from the HSE.  
d
   Excludes 2,158 UK Biobank participants aged 45-64 with missing data for body mass 
     index. 
f
   Excludes 1,925 UK Biobank participants aged 45-64 with missing data for weight. 
e
   Excludes 1,770 UK Biobank participants aged 45-64 with missing data for height.  
g
   Excludes 1,482 UK Biobank participants aged 45-64 with missing data for waist  
    circumference and 8 people for whom values outside the range 50–180 cm were obtained. 
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Table 4. Comparison of Frequency of Alcohol Consumption by Age and Sex in UK Biobank Participants With Data From the Health Survey for 
England 2008
a,b,c 
 
 Men Women 
 Age 45–54 years Age 55–64 years Age 45–54 years Age 55–64 years 
Alcohol 
consumption 
UK Biobank  
(n=62,082) 
% 
HSE  
(n=1,204) 
% 
UK Biobank  
(n=95,207) 
% 
HSE  
(n=1,085) 
% 
UK Biobank  
(n=79,904) 
% 
HSE 
(n=1,232) 
% 
UK Biobank  
(n=116,605) 
% 
HSE  
(n=1,123) 
% 
   Daily
d
 21.2 24 28.3 30 14.5 16 17.6 18 
   3–4 days a week 26.8 21 26.9 15 21.9 16 20.9 15 
   1–2 days a week 28.2 29 24.2 26 27.6 26 24.9 23 
   1–3 times a month 10.0 10 8.0 9 13.9 12 12.2 11 
   Special occasions
e
  7.4 9 6.8 11 13.8 16 15.0 21 
   Never
f 
6.6 8 5.8 9 8.3 12 9.5 12 
a
   See reference 9 for further information about HSE data. 
b
   HSE estimates are weighted for nonresponse bias. 
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c
   Excludes 1,013 UK Biobank participants aged 45-64  with missing data for alcohol intake or responded ‘prefer not to answer’.  
d
   HSE categories ‘almost every day’ and ‘5 or 6 days a week’ defined as ‘daily’.  
e
   HSE categories ‘once every couple of months’ and ‘once or twice in the past year’ defined as ‘special occasions’.  
f
   HSE category ‘not at all in the last 12 months/non–drinker’ defined as ‘never. 
Table 5. Comparison of Self-Reported Disease by Age and Sex in UK Biobank Participants With Data From the Health Survey for England 
Performed in 2006, 2009 or 2010
a,b,c 
 
 Men Women 
 Age 45–54 years Age 55–64 years Age 45–54 years Age 55–64 years 
Self-reported disease 
UK Biobank  
% 
HSE  
% 
UK Biobank  
% 
HSE  
% 
UK Biobank  
% 
HSE  
% 
UK Biobank  
% 
HSE  
% 
   Cardiovascular  
   disease
d
  
4.6 10.9 11.5 18.5 2.4 10.3 5.0 15.2 
   Ischaemic heart  
   disease
e
  
2.8 3.6 7.9 10.6 0.9 1.3 2.6 3.5 
   Stroke 0.8 1.2 1.9 3.0 0.6 0.9 1.0 2.3 
   Angina 1.8 2.4 5.3 8.0 0.7 1.2 2.1 3.2 
   Myocardial infarction 1.7 2.1 4.5 6.3 0.3 0.7 0.9 1.6 
   Abnormal heart 1.5 5.7 3.1 6.3 1.4 5.7 2.2 7.3 
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   rhythm  
   Hypertension
f
 21.2 27 34.4 39 15.4 16 27.4 29 
   Diabetes 4.5 8.1 7.8 10.5 2.4 3.5 6.3 8.0 
   Chronic kidney  
   disease   
0.2 1.1 0.3 1.5 0.2 1.2 0.2 1.9 
   Asthma
f
 11.7 12 9.9 13 13.0 16 11.8 15 
   Chronic obstructive  
   pulmonary disease 
0.1 1 0.4 3 0.1 0 0.4 2 
 
a
   See references 8, 10 and 11 for further information about HSE data.  
b
   HSE estimates are weighted for nonresponse bias. 
c
   HSE 2006 data were used for CVD, IHD, stroke, angina, MI and abnormal heart rhythm (n=1,123, n=1,015, n=1,141, n=1,050 respectively).  
    2009 estimates were used for hypertension (n=274, n=244, n=280, n=253 respectively) and diabetes (n=391, n=345, n=398, n=358  
    respectively). 2010 estimates were used for asthma (n=720, n=608, n=730, n=630 respectively) and COPD (n=720, n=608, n=730, n=631  
    respectively). Both 2009 and 2010 estimates (n=1,112, n=1,128, n=953, n=989 respectively) were used for CKD. 
d
   CVD includes angina, heart attack, stroke, heart murmur and irregular heart rhythm. 
e
   IHD includes heart attack or angina.
f
   HSE estimates only available to the nearest integer. 
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